Bernardo Goulart, MD, MS

Bernardo Goulart, MD, MS

Assistant Member
Clinical Research Division
Assistant Professor, Department of Medicine
University of Washington School of Medicine
Attending Physician
Seattle Cancer Care Alliance

Education

Federal University of Rio de Janeiro, MD, 1997
School of Pharmacy, University of Washington, MS (Master in Science) in the field of Pharmaceutical Outcomes Research and Pharmacoeconomics – Pharmaceutical Outcomes Research and Policy Program (PORPP), 2010

Research Focus

As an outcomes researcher, I analyze large regional and national databases to investigate the impact of different treatment practices on outcomes that matter to patients and society, including survival, hospitalizations, and direct medical costs, with a focus on thoracic cancers. 

Clinical Expertise

Thoracic cancers, particularly non-small cell lung cancer, malignant pleural mesothelioma, and thymic tumors.

Current Studies

National Cancer Institute (NCI) 12/31/2014-12/31/2017
5P30 CA015704-39 (PI: Gilliland)
CCSG Young Investigator Award, Fred Hutchinson Cancer Research Center

This proposal seeks to expand the knowledge on the use of precision oncology for non-small cell lung cancer (NSCLC) at the population level by validating a method for ascertainment of EGFR and ALK testing in SEER registries and by supporting the development of a patient cohort selected by positive EGFR and AKL test results with patient-level survival, hospitalization, and claims data from multiple insurance claims.
Role: Principal Investigator

Personalized Medicine Coalition (PMC) 07/01/2016 – 12/31/2017
Number: TBD (PI: Ramsey)
Clinical and Economic Value of Next Generation Sequencing-Based Diagnostic Testing in Cancer Care.

This project will employ decision analytic models and a value-of-information approach to determine: (1) the cost-effectiveness of the use of next generation sequencing genetic testing as a guide for treatment choices in stage IV non-small cell lung cancer and melanoma; (2) the value of future research in mitigating current uncertainty regarding the use of next generation sequencing.
Role: Co-investigator.

Gregory Fund Foundation 04/01/12 – 12/31/2015
(PI: Goulart)
Outcomes and Costs of Low-Dose Computed Tomography for Early Detection of Lung Cancer: a Pilot Study

The goal of this study is to establish feasibility of a prospective registry of patients referred for lung cancer screening with Low-Dose Computed Tomography at the Seattle Cancer Care Alliance that includes healthcare resource utilization, medical costs, screening test performance, QoL, and complications from screening.
Role: Principal Investigator

National Cancer Institute (NCI) 9/18/2015 – 9/17/2016
HHSN26100007 (PI: Goulart)
Assessing Molecular Profiling in Non-Small Cell Lung Cancer at the Population Level: A Validation Study of Natural Language Processing Algorithms for SEER

This project proposes to develop Natural Language Processing (NLP) algorithms to ascertain use, results, and techniques employed for EGFR and ALK testing, respectively, from SEER electronic pathology reports of stage IV non-squamous NSCLC registry cases.
Role: Co-Principal Investigator

National Cancer Institute (NCI) 12/31/2014-12/31/2017
5P30 CA015704-39 (PI: Gilliland)
CCSG Young Investigator Award, Fred Hutchinson Cancer Research Center
Real-World Impact of Target Therapies for EGFR and ALK Positive Advanced Non-Small Cell Lung Cancer (NSCLC): A Novel Population-based Retrospective Cohort Study

An extension of the NCI HHSN26100007 validation study for ascertainment of EGFR and ALK test results from SEER pathology reports, this research project involves the development of an unique retrospective cohort of EGFR and ALK positive stage IV non-small cell lung cancer patients whose records from the Fred Hutchinson Cancer Surveillance System (CSS) are linked to longitudinal outpatient, inpatient, and pharmacy claims. This cohort leverages longitudinal data on the care delivered to molecularly selected patient subgroups and the impact of different patterns of use of target therapies on survival, hospitalizations, and direct medical costs.



Additional Links & Information

Related Labs & Projects

View all labs & projects >
Bernardo Goulart, MD

Contact Information

Phone
(206) 288 6465
Fax
(206) 288-1435
Email
Additional contact

Mail Stop: M3-B232